Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10770837 | Biochemical and Biophysical Research Communications | 2005 | 7 Pages |
Abstract
Human LCAT-like lysophospholipase (LLPL), or lysophospholipase 3, was first identified in vitro, in foam cells derived from THP-1 cells. We demonstrated that LLPL was present in foam cells in the severe atherosclerotic lesions that develop in apolipoprotein E-null (apoEâ/â) mice. This indicated that LLPL might affect lipid metabolisms in foam cells and, therefore, atherogenesis. Accordingly, we created LLPL-knockout mice by gene targeting and crossed them with apoEâ/â mice. We showed that the absence of LLPL increased lesion formation markedly in apoEâ/â mice but had little effect on the plasma-lipid profile. In addition, LLPL-deficient peritoneal macrophages were more sensitive to apoptosis induced by exposure to oxidized low-density lipoprotein. LLPL might provide a link between apoptosis in macrophages and atherogenesis. Our data demonstrate that LLPL activity is anti-atherogenic and indicate that the regulation of this enzyme might be a novel drug target for the treatment of atherosclerosis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Yoshio Taniyama, Hiromitsu Fuse, Tomoko Satomi, Ryuichi Tozawa, Yoshitaka Yasuhara, Kozo Shimakawa, Sachio Shibata, Masahiko Hattori, Mitsugu Nakata, Shigehisa Taketomi,